05/15/2025 | Press release | Distributed by Public on 05/16/2025 00:11
- -
The Nikkei Online Edition (dated May 5th) introduced our AI-based co-creation project with Chugai Pharmaceutical. The project uses the AI drug discovery support service "Drug Discovery AI Factory."
FRONTEO and Chugai Pharmaceutical Collaborate to Discover Drug Targets Using AI https://www.nikkei.com/article/DGXZQOUC15BP40V10C25A5000000/
About FRONTEO's AI drug discovery support service "Drug Discovery AI Factory (DDAIF)" https://lifescience.fronteo.com/products/drug-discovery-ai-factory/ "FRONTEO Drug Discovery AI Factory (DDAIF)" is an AI drug discovery support service that combines the knowledge of FRONTEO's drug discovery researchers and AI engineers with "KIBIT" (patented in Japan, the US and Europe), an AI specialized in natural language processing. It strongly supports researchers' decision-making in drug development by analyzing disease-related gene networks and building hypotheses about target candidates. This service has already been introduced at several major pharmaceutical companies and is accumulating a proven track record.
[Reference: Co-creation project with pharmaceutical companies]
- FRONTEO and Chugai Pharmaceutical Launch Co-Creation Project for Target Discovery Using Drug Discovery AI Factory
- EA Pharma and FRONTEO launch co-creation project to explore drug discovery targets using AI
- FRONTEO and Eisai Launch Co-Creation Project for Target Discovery Using Drug Discovery AI Factory
- FRONTEO and Maruishi Pharmaceutical Launch Co-Creation Project for Biomarker Discovery Using Drug Discovery AI Factory
- FRONTEO and UBE launch co-creation project on drug repositioning using Drug Discovery AI Factory
[Reference: Joint research projects with academia]
- FRONTEO and Tokyo University of Science begin joint research to identify new drug discovery targets using the "Drug Discovery AI Factory"
- FRONTEO and Kumamoto University begin joint research to discover new cancer treatments using Drug Discovery AI Factory